AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31904175 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 29789130 — intervention group
Group type: EXPERIMENTAL
Intervention: Red wine (300 ml/day for men, 230 ml/day for women)
Number of subjects: 24
Study 29789130 — intervention group
Group type: COMPARATOR
Intervention: Dealcoholized red wine (DRW)
Number of subjects: 24
Study 29789130 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 24
Study 29789130 — intervention group
Group type: COMPARATOR
Intervention: Baseline comparison with healthy volunteers
Number of subjects: 24
Study 28316276 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan (0.2 μg/kg/min for 1 hour, followed by 0.1 μg/kg/min for 23 hours)
Number of subjects: 849
Study 28316276 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 849
Study 28316276 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 849
Study 28316276 — intervention group
Group type: COMPARATOR
Intervention: Levosimendan and Placebo
Number of subjects: 849
Study 26179377 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening-before regimen of sodium picosulfate/magnesium citrate (SPMC)
Number of subjects: 490
Study 26179377 — intervention group
Group type: EXPERIMENTAL
Intervention: Same-day regimen of sodium picosulfate/magnesium citrate (SPMC)
Number of subjects: 490
Study 26179377 — intervention group
Group type: COMPARATOR
Intervention: Evening-before polyethylene glycol (PEG)
Number of subjects: 490
Study 23176401 — intervention group
Group type: COMPARATOR
Intervention: Low-flux hemodialysis (HD)
Number of subjects: 24
Study 23176401 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flux hemodiafiltration (OHDF)
Number of subjects: 24
Study 21765345 — intervention group
Group type: EXPERIMENTAL
Intervention: Amifostine (10-100 mg/kg, intraperitoneal injection)
Number of subjects: 100
Study 18506008 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambrisentan 5 mg
Number of subjects: 394
Study 18506008 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambrisentan 10 mg
Number of subjects: 394
Study 18506008 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambrisentan 2.5 mg
Number of subjects: 394
Study 18506008 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambrisentan
Number of subjects: 394
Study 18506008 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambrisentan monotherapy
Number of subjects: 394
Study 16805144 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide 250 mg daily
Number of subjects: 400
Study 16805144 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study 16805144 — intervention group
Group type: EXPERIMENTAL
Intervention: Acclimatization in the pretrial week
Number of subjects: 400
Study 16805144 — intervention group
Group type: EXPERIMENTAL
Intervention: Slower ascent rate
Number of subjects: 400
Study 16805144 — intervention group
Group type: EXPERIMENTAL
Intervention: Rest days
Number of subjects: 400
Study 14555501 — intervention group
Group type: EXPERIMENTAL
Intervention: Measuring six lesions bidimensionally
Number of subjects: 36
Study 14555501 — intervention group
Group type: EXPERIMENTAL
Intervention: Measuring four lesions undimensionally
Number of subjects: 36
Study 14555501 — intervention group
Group type: EXPERIMENTAL
Intervention: Measuring six or more lesions bidimensionally
Number of subjects: 36
Study 10617696 — intervention group
Group type: EXPERIMENTAL
Intervention: Intubation and suctioning (INT)
Number of subjects: 2094
Study 10617696 — intervention group
Group type: COMPARATOR
Intervention: Expectant management (EXP)
Number of subjects: 2094
Study 1390316 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with carboplatin 400 mg/m2 day 1 and 5-FU 1 g/m2/d as a continuous infusion days 1 through 5 every 3 weeks, given to 108 patients.
Number of subjects: 219
Study 1390316 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy group (not specified as control).
Number of subjects: 219
Study 1390316 — intervention group
Group type: COMPARATOR
Intervention: Control group (locoregional treatment alone).
Number of subjects: 219
Study 3888433 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 66
Study 3888433 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen with aminoglutethimide
Number of subjects: 66
Study 31120943 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccination (inactivated quadrivalent influenza vaccine)
Number of subjects: 1838
Study 31120943 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1838
Study 31120943 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccination
Number of subjects: 1838
Study 30428847 — intervention group
Group type: EXPERIMENTAL
Intervention: Adefovir (ADV)
Number of subjects: 329
Study 30428847 — intervention group
Group type: EXPERIMENTAL
Intervention: Emtricitabine (FTC)
Number of subjects: 329
Study 30428847 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine (LMV)
Number of subjects: 329
Study 30428847 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF)
Number of subjects: 329
Study 30428847 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF plus LMV
Number of subjects: 329
Study 30428847 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 329
Study 26517576 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic variceal ligation (EVL) + β-blocker
Number of subjects: 72
Study 26517576 — intervention group
Group type: EXPERIMENTAL
Intervention: Transjugular intrahepatic portosystemic shunt (TIPS)
Number of subjects: 72
Study 26517576 — intervention group
Group type: EXPERIMENTAL
Intervention: TIPS
Number of subjects: 72
Study 24092275 — intervention group
Group type: EXPERIMENTAL
Intervention: CISTIMEV PLUS(®), 1 tablet daily for 30 days
Number of subjects: 83
Study 24092275 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 83
Study 22107835 — intervention group
Group type: EXPERIMENTAL
Intervention: Xiaozhang Tie (traditional Chinese herbal cataplasm)
Number of subjects: 100
Study 22107835 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 100
Study 22107835 — intervention group
Group type: EXPERIMENTAL
Intervention: Xiaozhang Tie
Number of subjects: 100
Study 22107835 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 20829648 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagery Rehearsal Therapy (IRT)
Number of subjects: 399
Study 20829648 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure
Number of subjects: 399
Study 20829648 — intervention group
Group type: EXPERIMENTAL
Intervention: Recording (keeping a diary)
Number of subjects: 399
Study 20829648 — intervention group
Group type: COMPARATOR
Intervention: Waiting list
Number of subjects: 399
Study 17544328 — intervention group
Group type: EXPERIMENTAL
Intervention: Sports drinks (three commercially available)
Number of subjects: 0
Study 17544328 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 0
Study 16883904 — intervention group
Group type: EXPERIMENTAL
Intervention: Bushen Qiangji Granule (BQG)
Number of subjects: 68
Study 16883904 — intervention group
Group type: COMPARATOR
Intervention: Combined treatment (BQG + sulfasalazine)
Number of subjects: 68
Study 14661537 — intervention group
Group type: EXPERIMENTAL
Intervention: Total knee replacement
Number of subjects: 15
Study 14661537 — intervention group
Group type: EXPERIMENTAL
Intervention: Total hip replacement
Number of subjects: 15
Study 11022383 — intervention group
Group type: EXPERIMENTAL
Intervention: Erbium:YAG laser
Number of subjects: 77
Study 11022383 — intervention group
Group type: COMPARATOR
Intervention: Conventional handpieces
Number of subjects: 77
Study 7910472 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled salmeterol 100 micrograms
Number of subjects: 12
Study 7910472 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled salmeterol (cumulative doses of up to 400 micrograms)
Number of subjects: 12
Study 7910472 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 3540072 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous streptokinase (1.5 million IU/h)
Number of subjects: 1741
Study 3540072 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1741
Study 29467024 — intervention group
Group type: EXPERIMENTAL
Intervention: Male synthetic sling
Number of subjects: 0
Study 29467024 — intervention group
Group type: COMPARATOR
Intervention: Artificial urinary sphincter (AUS)
Number of subjects: 0
Study 29467024 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour urinary pad test
Number of subjects: 0
Study 29467024 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical review
Number of subjects: 0
Study 26980352 — intervention group
Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG laser irradiated dentin
Number of subjects: 30
Study 26980352 — intervention group
Group type: COMPARATOR
Intervention: Control group (no surface treatment)
Number of subjects: 30
Study 26417059 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonolysis
Number of subjects: 242
Study 26417059 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 242
Study 24281606 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin treatment on half of the wound surface
Number of subjects: 8
Study 24281606 — intervention group
Group type: COMPARATOR
Intervention: No insulin treatment on the other half of the wound surface
Number of subjects: 8
Study 24281606 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin treatment
Number of subjects: 8
Study 24281606 — intervention group
Group type: COMPARATOR
Intervention: No insulin treatment
Number of subjects: 8
Study 21364488 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Training (AT)
Number of subjects: 82
Study 21364488 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Aerobic and Resistance Training (AT/RT)
Number of subjects: 82
Study 21364488 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 82
Study 19850735 — intervention group
Group type: EXPERIMENTAL
Intervention: exercise + fortified milk
Number of subjects: 180
Study 19850735 — intervention group
Group type: EXPERIMENTAL
Intervention: exercise
Number of subjects: 180
Study 19850735 — intervention group
Group type: EXPERIMENTAL
Intervention: fortified milk
Number of subjects: 180
Study 19850735 — intervention group
Group type: COMPARATOR
Intervention: control
Number of subjects: 180
Study 17148968 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic formulation of stavudine (40 mg twice daily)
Number of subjects: 12
Study 17148968 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic formulation of lamivudine (150 mg twice daily)
Number of subjects: 12
Study 17148968 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic formulation of nevirapine (200 mg twice daily)
Number of subjects: 12
Study 14982247 — intervention group
Group type: EXPERIMENTAL
Intervention: Reading with Phoneme
Number of subjects: 410
Study 14982247 — intervention group
Group type: EXPERIMENTAL
Intervention: Reading with Rhyme and Phoneme
Number of subjects: 410
Study 14982247 — intervention group
Group type: EXPERIMENTAL
Intervention: Reading with Rhyme
Number of subjects: 410
Study 14982247 — intervention group
Group type: COMPARATOR
Intervention: Taught control condition (Reading)
Number of subjects: 410
Study 11682370 — intervention group
Group type: EXPERIMENTAL
Intervention: Early enrollment (first-month accrual)
Number of subjects: 28992
Study 11682370 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative enrollment during the first month over target sample size
Number of subjects: 28992
Study 11682370 — intervention group
Group type: EXPERIMENTAL
Intervention: Masking (double-blind vs. single or unblinded studies)
Number of subjects: 28992
Study 11682370 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid early accrual (additional patients accrued in the first month)
Number of subjects: 28992
Study 11682370 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical significance in favor of an experimental arm
Number of subjects: 28992
Study 9022561 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss
Number of subjects: 2182
Study 9022561 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium reduction
Number of subjects: 2182
Study 9022561 — intervention group
Group type: COMPARATOR
Intervention: Stress management
Number of subjects: 2182
Study 9022561 — intervention group
Group type: COMPARATOR
Intervention: Supplementation with calcium
Number of subjects: 2182
Study 9022561 — intervention group
Group type: COMPARATOR
Intervention: Supplementation with magnesium
Number of subjects: 2182
Study 9022561 — intervention group
Group type: COMPARATOR
Intervention: Supplementation with potassium
Number of subjects: 2182
Study 9022561 — intervention group
Group type: COMPARATOR
Intervention: Supplementation with fish oil
Number of subjects: 2182
Study 7633298 — intervention group
Group type: EXPERIMENTAL
Intervention: Letter sent to group E patients suggesting they make an appointment with a physician specializing in alcoholism.
Number of subjects: 362
Study 7633298 — intervention group
Group type: COMPARATOR
Intervention: No letter sent to group C patients.
Number of subjects: 362
Study 2701324 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Treatment Program
Number of subjects: 0
Study 2701324 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone patients receiving additional medication for cocaine dependence
Number of subjects: 0
Study 2701324 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient treatment (28 days)
Number of subjects: 0
Study 2701324 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient treatment (day hospital or behavioral treatment)
Number of subjects: 0
Study 2701324 — intervention group
Group type: COMPARATOR
Intervention: Inpatient treatment
Number of subjects: 0
Study 2701324 — intervention group
Group type: COMPARATOR
Intervention: Outpatient treatment
Number of subjects: 0
Study 302028 — intervention group
Group type: COMPARATOR
Intervention: Placebo stimulation
Number of subjects: 20
Study 302028 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous nerve stimulation (TNS)
Number of subjects: 20
Study 302028 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoprenaline inhalation test
Number of subjects: 20
Study 30630461 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo (deliberate positive information)
Number of subjects: 24
Study 30630461 — intervention group
Group type: COMPARATOR
Intervention: Standard information (water)
Number of subjects: 24
Study 29179766 — intervention group
Group type: EXPERIMENTAL
Intervention: Water treadmill at stifle height and 1.39 m/s
Number of subjects: 15
Study 29179766 — intervention group
Group type: EXPERIMENTAL
Intervention: Water treadmill at carpus height and 1.39 m/s
Number of subjects: 15
Study 29179766 — intervention group
Group type: COMPARATOR
Intervention: Dry treadmill (control) at all three speeds
Number of subjects: 15
Study 25917730 — intervention group
Group type: EXPERIMENTAL
Intervention: Superior hypogastric plexus neurolysis (SHN)
Number of subjects: 24
Study 25917730 — intervention group
Group type: COMPARATOR
Intervention: Bladder hydrodistention (HD)
Number of subjects: 24
Study 23692260 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol succinate or olmesartan medoxomil (antihypertensive treatment)
Number of subjects: 44
Study 23692260 — intervention group
Group type: COMPARATOR
Intervention: Control (healthy controls)
Number of subjects: 44
Study 21745623 — intervention group
Group type: EXPERIMENTAL
Intervention: BTE (333 mg)
Number of subjects: 36
Study 21745623 — intervention group
Group type: COMPARATOR
Intervention: Placebo (powdered barley tea)
Number of subjects: 36
Study 19563637 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive biomarkers of airway inflammation and early lung function measurements
Number of subjects: 250
Study 19563637 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated measurements of lung function tests and inflammatory markers in exhaled breath, blood, and faeces
Number of subjects: 250
Study 19563637 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 250
Study 16998649 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine (3 to 12 mg per day)
Number of subjects: 28
Study 16998649 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 14967982 — intervention group
Group type: EXPERIMENTAL
Intervention: Same-day scheduling
Number of subjects: 0
Study 11096003 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin treatment
Number of subjects: 535
Study 11096003 — intervention group
Group type: COMPARATOR
Intervention: Antibiotic therapy (not specified)
Number of subjects: 535
Study 9282188 — intervention group
Group type: EXPERIMENTAL
Intervention: QuickCast
Number of subjects: 30
Study 9282188 — intervention group
Group type: COMPARATOR
Intervention: Conventional short-arm fibreglass tape cast
Number of subjects: 30
Study 8352621 — intervention group
Group type: EXPERIMENTAL
Intervention: Q-switched Nd:YAG laser (1064 nm, 10 ns, 5 Hz) at 10 to 12 J/cm2
Number of subjects: 25
Study 8352621 — intervention group
Group type: EXPERIMENTAL
Intervention: Q-switched Nd:YAG laser (1064 nm, 10 ns, 5 Hz) at 6, 8, 10, or 12 J/cm2
Number of subjects: 25
Study 8352621 — intervention group
Group type: EXPERIMENTAL
Intervention: Q-switched Nd:YAG laser (1064 nm, 10 ns, 5 Hz)
Number of subjects: 25
Study 8352621 — intervention group
Group type: EXPERIMENTAL
Intervention: Q-switched Nd:YAG laser (1064 nm)
Number of subjects: 25
Study 3304950 — intervention group
Group type: EXPERIMENTAL
Intervention: cyclandelate 800 mg twice daily
Number of subjects: 40
Study 3304950 — intervention group
Group type: COMPARATOR
Intervention: flunarizine 5 mg daily
Number of subjects: 40
Study 29880288 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure lowering
Number of subjects: 10615
Study 29880288 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 10615
Study 27823681 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel 5mg daily
Number of subjects: 2000
Study 27823681 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel 75mg daily
Number of subjects: 2000
Study 24602602 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-day course of amoxicillin/clavulanic acid 625 mg orally 8-hourly for 4 days after initial intravenous treatment
Number of subjects: 94
Study 24602602 — intervention group
Group type: COMPARATOR
Intervention: 1-day course of amoxicillin/clavulanic acid 1.2g intravenously followed by placebo orally
Number of subjects: 94
Study 22828247 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory loads (light: 8.4 cm H2O/L/s, moderate: 23.4 cm H2O/L/s, severe: 70.5 cm H2O/L/s) with deep breaths during normal breathing
Number of subjects: 35
Study 22828247 — intervention group
Group type: EXPERIMENTAL
Intervention: Sudden removal of dyspnoea with a large increase in tidal volume (V(T))
Number of subjects: 35
Study 22828247 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative assessment of 'respiratory pleasure'
Number of subjects: 35
Study 22828247 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in tidal volume (V(T)) after removal of respiratory loading
Number of subjects: 35
Study 20512042 — intervention group
Group type: EXPERIMENTAL
Intervention: Silexan (80 mg/day)
Number of subjects: 221
Study 20512042 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 221
Study 18665826 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 microg filgrastim
Number of subjects: 47
Study 18665826 — intervention group
Group type: COMPARATOR
Intervention: 50 microg lenograstim
Number of subjects: 47
Study 15942550 — intervention group
Group type: EXPERIMENTAL
Intervention: Oat bran cereal containing beta glucan (3 g daily)
Number of subjects: 152
Study 15942550 — intervention group
Group type: COMPARATOR
Intervention: Corn cereal without soluble fiber
Number of subjects: 152
Study 12843352 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross‐spectral analysis (CSA) in patients with high-degree M1 stenosis
Number of subjects: 40
Study 12843352 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross‐spectral analysis (CSA) in patients with low-degree M1 stenosis
Number of subjects: 40
Study 12843352 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 40
Study 10770343 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical alitretinoin 0.1% gel
Number of subjects: 268
Study 10770343 — intervention group
Group type: COMPARATOR
Intervention: Vehicle gel (control)
Number of subjects: 268
Study 10770343 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label alitretinoin treatment after blinded phase
Number of subjects: 268
Study 8721798 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholesterol-lowering treatments (specific types not detailed)
Number of subjects: 0
Study 8721798 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 8721798 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone treatments
Number of subjects: 0
Study 8721798 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrate trials
Number of subjects: 0
Study 1815423 — intervention group
Group type: EXPERIMENTAL
Intervention: Finger oscillometric blood pressure device
Number of subjects: 76
Study 1815423 — intervention group
Group type: COMPARATOR
Intervention: Random-zero sphygmomanometer
Number of subjects: 76
Study 6139422 — intervention group
Group type: EXPERIMENTAL
Intervention: Luteinizing hormone releasing hormone (LHRH)
Number of subjects: 50
Study 6139422 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 31390654 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational interventions in pathology education
Number of subjects: 54
Study 29173829 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment process by health care professionals
Number of subjects: 0
Study 29173829 — intervention group
Group type: EXPERIMENTAL
Intervention: Health care professionals' communication skills
Number of subjects: 0
Study 29173829 — intervention group
Group type: EXPERIMENTAL
Intervention: Consideration of research designs
Number of subjects: 0
Study 27009061 — intervention group
Group type: EXPERIMENTAL
Intervention: START intervention
Number of subjects: 240
Study 27009061 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 240
Study 25121977 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant cessation advice
Number of subjects: 0
Study 25121977 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0